The Constellation of Risk Factors and Paraneoplastic Syndromes in Cholangiocarcinoma: Integrating the Endocrine Panel Amid Tumour-Related Biology (A Narrative Review)

Our plain-English summary of The Constellation of Risk Factors and Paraneoplastic Syndromes in Cholangiocarcinoma: Integrating the Endocrine Panel Amid Tumour-Related Biology (A Narrative Review), by M.L. Ciobica, B.A. Sandulescu, L.M. Chicea, et al (Biology, 2024).

The study

• Authors: M.L. Ciobica, B.A. Sandulescu, L.M. Chicea, M. Iordache, M.L. Groseanu, M. Carsote, C. Nistor, A.M. Radu
• Journal: Biology
• Published: 2024;13(9)
• Type of article: Review
• Cited by: 1 article, as counted by NIH iCite
• Read it: PubMed · Publisher · Free full text

Abstract

Cholangiocarcinomas (CCAs), a heterogeneous group of challenging malignant tumours which originate from the biliary epithelium, are associated with an alarming increasing incidence during recent decades that varies between different regions of the globe. Thus, awareness represents the key operating factor. Our purpose was to overview the field of CCAs following a double perspective: the constellation of the risk factors, and the presence of the paraneoplastic syndromes, emphasizing the endocrine features amid the entire multidisciplinary panel. This is a narrative review. A PubMed-based search of English-language original articles offered the basis of this comprehensive approach. Multiple risk factors underlying different levels of statistical evidence have been listed such as chronic biliary diseases and liver conditions, inflammatory bowel disease, parasitic infections (e.g., Opisthorchis viverrini, Clonorchis sinensis), lifestyle influence (e.g., alcohol, smoking), environmental exposure (e.g., thorotrast, asbestos), and certain genetic and epigenetic interplays. With regard to the endocrine panel, a heterogeneous spectrum should be taken into consideration: non-alcoholic fatty liver disease, obesity, type 2 diabetes mellitus, and potential connections with vitamin D status, glucagon-like peptide 1 receptor, or the galanin system, respectively, with exposure to sex hormone therapy. Amid the numerous dermatologic, hematologic, renal, and neurologic paraneoplastic manifestations in CCAs, the endocrine panel is less described. Humoral hypercalcaemia of malignancy stands as the most frequent humoral paraneoplastic syndrome in CCAs, despite being exceptional when compared to other paraneoplastic (non-endocrine) manifestations and to its reported frequency in other (non-CCAs) cancers (it accompanies 20-30% of all cancers). It represents a poor prognosis marker in CCA; it may be episodic once the tumour relapses. In addition to the therapy that targets the originating malignancy, hypercalcaemia requires the administration of bisphosphonates (e.g., intravenous zoledronic acid) or denosumab. Early detection firstly helps the general wellbeing of a patient due to a prompt medical control of high serum calcium and it also provides a fine biomarker of disease status in selected cases that harbour the capacity of PTHrP secretion. The exact molecular biology and genetic configuration of CCAs that display such endocrine traits is still an open matter, but humoral hypercalcaemia adds to the overall disease burden.

In plain English

This article was a narrative review, not a new study. The authors searched PubMed for English-language original articles, from inception until June 2024, on cholangiocarcinoma, a cancer arising from the lining of the bile ducts. They described reported risk factors and paraneoplastic syndromes (conditions the tumour causes elsewhere in the body), with emphasis on hormone-related features. Asbestos appeared in one short passage on environmental exposure. The authors wrote that several earlier studies had found a link between asbestos exposure and cholangiocarcinoma, and that cumulative asbestos exposure had been shown to increase the risk of intrahepatic (inside the liver) but not extrahepatic cholangiocarcinoma. The review named no fiber types and gave no risk figures for asbestos. Other listed risk factors included primary sclerosing cholangitis, bile duct cysts, liver flukes and thorotrast. The authors described humoral hypercalcaemia (high blood calcium) as the most frequent humoral paraneoplastic syndrome in cholangiocarcinoma, though exceptional. They concluded that endocrine evidence from clinical trials remained far from generous, which is why they chose a narrative rather than a systematic review.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: Narrative review of published literature (not a systematic review; no new data collected)
• Who was studied: English-language original articles found through a PubMed search, from inception until June 2024, on cholangiocarcinoma (CCA), including intrahepatic (iCCA), perihilar (pCCA) and distal (dCCA) types
• Exposure: Many reported risk factors for cholangiocarcinoma. Asbestos is covered only briefly as an environmental exposure, alongside thorotrast. No fiber types, jobs or doses are specified.
• Main results:
  • The review reported, citing other studies, that a link between asbestos exposure and cholangiocarcinoma had been found. It stated that cumulative asbestos exposure had been shown to increase the risk of intrahepatic (iCCA) but not extrahepatic (eCCA) cholangiocarcinoma.
  • The review reported, citing other studies, that the risk of cholangiocarcinoma was three hundred times higher in people exposed to thorotrast, a banned radiographic contrast agent.
  • The review reported, citing other studies, a 400-fold increase in cholangiocarcinoma risk in patients with primary sclerosing cholangitis compared with the general population.
  • The authors described humoral hypercalcaemia of malignancy as the most frequent humoral paraneoplastic syndrome in cholangiocarcinoma, though exceptional compared with other paraneoplastic manifestations. They noted it accompanies 20 to 30% of malignancies in general. They described it as a poor prognosis marker in cholangiocarcinoma.
• The authors' conclusion: The authors concluded that hormone-related features in cholangiocarcinoma involve a complex set of interplays. They stated that humoral hypercalcaemia, though rare, has been reported, that endocrine evidence from clinical trials remains far from generous, and that emerging hormonal biomarkers are expected for daily practice.
• Limitations the authors state:
  • Because endocrine evidence from clinical trials is limited, the authors performed a narrative analysis rather than a systematic review.
  • The authors stated that the current level of evidence on paraneoplastic syndromes in cholangiocarcinoma remains mostly low.
  • The authors stated that some topics, such as thyroid hormone involvement and adrenal metastases with adrenal insufficiency, were outside the scope of the review.

Topics

Medical terms in this study, explained in our Lexicon: Epithelium, Environmental Exposure, Prognosis, Biomarker.

Related studies

• Mesothelioma and anti-Ma paraneoplastic syndrome; heterogeneity in immunogenic tumours increases — H.A. Archer, A. Panopoulou, et al. (2014)
• Asbestos exposure as an additional risk factor for small duct intrahepatic cholangiocarcinoma: a pilot study — F. Vasuri, M. Deserti, et al. (2023)
• Multiple Myeloma and Occupational Risk Factors: A Narrative Review — A. Hejrati, S. Parvin, et al. (2024)
• CYP1A1 and CYP1B1 polymorphisms as modifying factors in patients with pneumoconiosis and occupationally related tumours: A pilot study — J. Schneider, U. Bernges (2009)
• Spontaneous pneumothorax and pulmonary malignant disease--a syndrome sometimes associated with cavitating tumours. Report of nine new cases, four with metastases and five with primary bronchial tumours — F.W. Wright (1976)
• The Proportion of Occupationally Related Cholangiocarcinoma: A Tertiary Hospital Study in Northeastern Thailand — A. Seeherunwong, N. Chaiear, et al. (2022)

Browse return to medical research.